{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Gastroesophageal+Junction&page=4",
    "query": {
      "condition": "Adenocarcinoma Gastroesophageal Junction",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 343,
    "total_pages": 35,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Gastroesophageal+Junction&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Gastroesophageal+Junction&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T16:50:19.742Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06324357",
      "title": "Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Metastatic Gastric Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Esophageal Adenocarcinoma",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Zongertinib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab emtansine",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "zanidatamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 768,
      "start_date": "2024-06-28",
      "completion_date": "2029-01-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-14T16:50:19.742Z",
      "location_count": 26,
      "location_summary": "Cerritos, California • Los Angeles, California • Orange, California + 18 more",
      "locations": [
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06324357"
    },
    {
      "nct_id": "NCT04069273",
      "title": "Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Cancer",
        "GastroEsophageal Cancer",
        "Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab Monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Harry H Yoon",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2020-12-01",
      "completion_date": "2027-12-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-14T16:50:19.742Z",
      "location_count": 2,
      "location_summary": "Rochester, Minnesota • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04069273"
    },
    {
      "nct_id": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignancies"
      ],
      "interventions": [
        {
          "name": "INCAGN01949",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Biosciences International Sàrl",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2017-10-09",
      "completion_date": "2019-09-17",
      "has_results": true,
      "last_update_posted_date": "2022-09-27",
      "last_synced_at": "2026-10-14T16:50:19.742Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03241173"
    },
    {
      "nct_id": "NCT04260191",
      "title": "Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gastric and Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "AMG 910",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 15,
      "start_date": "2020-06-29",
      "completion_date": "2022-06-02",
      "has_results": true,
      "last_update_posted_date": "2024-01-25",
      "last_synced_at": "2026-10-14T16:50:19.742Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Orange, California • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04260191"
    },
    {
      "nct_id": "NCT03641313",
      "title": "Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Metastatic Gastric Adenocarcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Unresectable Gastric Adenocarcinoma",
        "Unresectable Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Berzosertib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography Assisted Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Endoscopic Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2020-11-16",
      "completion_date": "2027-01-28",
      "has_results": true,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-14T16:50:19.742Z",
      "location_count": 31,
      "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 25 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03641313"
    },
    {
      "nct_id": "NCT06265285",
      "title": "Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Esophageal Squamous Cell Carcinoma",
        "Advanced Renal Cell Carcinoma",
        "Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage IIB Cutaneous Melanoma AJCC v8",
        "Clinical Stage IIC Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8",
        "Esophageal Carcinoma",
        "Gastroesophageal Junction Adenocarcinoma",
        "Hepatocellular Carcinoma",
        "Locally Advanced Urothelial Carcinoma",
        "Lung Non-Small Cell Carcinoma",
        "Malignant Solid Neoplasm",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Cutaneous Melanoma",
        "Metastatic Esophageal Squamous Cell Carcinoma",
        "Metastatic Head and Neck Squamous Cell Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Recurrent Esophageal Squamous Cell Carcinoma",
        "Recurrent Head and Neck Squamous Cell Carcinoma",
        "Renal Cell Carcinoma",
        "Stage III Renal Cell Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8",
        "Stage IV Renal Cell Cancer AJCC v8",
        "Unresectable Cutaneous Melanoma",
        "Unresectable Esophageal Squamous Cell Carcinoma",
        "Urothelial Carcinoma",
        "Unresectable Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Home Health Encounter",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Patient Monitoring",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-04-30",
      "completion_date": "2027-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-14T16:50:19.742Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06265285"
    },
    {
      "nct_id": "NCT01178944",
      "title": "Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Gastroesophageal Junction",
        "Esophageal Undifferentiated Carcinoma",
        "Gastric Adenocarcinoma",
        "Gastric Squamous Cell Carcinoma",
        "Recurrent Esophageal Adenocarcinoma",
        "Recurrent Esophageal Squamous Cell Carcinoma",
        "Recurrent Gastric Carcinoma",
        "Stage IIIB Esophageal Adenocarcinoma",
        "Stage IIIB Esophageal Squamous Cell Carcinoma",
        "Stage IIIB Gastric Cancer",
        "Stage IIIC Esophageal Adenocarcinoma",
        "Stage IIIC Esophageal Squamous Cell Carcinoma",
        "Stage IIIC Gastric Cancer",
        "Stage IV Esophageal Adenocarcinoma",
        "Stage IV Esophageal Squamous Cell Carcinoma",
        "Stage IV Gastric Cancer",
        "Undifferentiated Gastric Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Pralatrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2010-09",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2017-12-13",
      "last_synced_at": "2026-10-14T16:50:19.742Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Rochester, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01178944"
    },
    {
      "nct_id": "NCT02991547",
      "title": "Surveillance of Patients With Adenocarcinoma of the Gastroesophageal Junction or Esophagus",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adenocarcinoma Esophagus"
      ],
      "interventions": [
        {
          "name": "Observational",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The Guthrie Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 3,
      "start_date": "2016-12",
      "completion_date": "2018-08-03",
      "has_results": false,
      "last_update_posted_date": "2024-02-13",
      "last_synced_at": "2026-10-14T16:50:19.742Z",
      "location_count": 2,
      "location_summary": "Corning, New York • Sayre, Pennsylvania",
      "locations": [
        {
          "city": "Corning",
          "state": "New York"
        },
        {
          "city": "Sayre",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02991547"
    },
    {
      "nct_id": "NCT03615326",
      "title": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastric Neoplasms",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "S-1",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 738,
      "start_date": "2018-10-05",
      "completion_date": "2025-11-12",
      "has_results": true,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-10-14T16:50:19.742Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Monterey, California • Orange, California + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03615326"
    },
    {
      "nct_id": "NCT01939275",
      "title": "64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adenocarcinoma of the Gastroesophageal Junction",
        "Diffuse Adenocarcinoma of the Stomach",
        "Intestinal Adenocarcinoma of the Stomach",
        "Mixed Adenocarcinoma of the Stomach",
        "Recurrent Gastric Cancer",
        "Stage IA Gastric Cancer",
        "Stage IB Gastric Cancer",
        "Stage IIA Gastric Cancer",
        "Stage IIB Gastric Cancer",
        "Stage IIIA Gastric Cancer",
        "Stage IIIB Gastric Cancer",
        "Stage IIIC Gastric Cancer",
        "Stage IV Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "copper Cu 64-DOTA-trastuzumab",
          "type": "RADIATION"
        },
        {
          "name": "positron emission tomography",
          "type": "DEVICE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DEVICE",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2014-11-19",
      "completion_date": "2024-08-05",
      "has_results": true,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-10-14T16:50:19.742Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01939275"
    }
  ]
}